Michael Narachi

Michael Narachi

Director/Board Member at ULTRAGENYX PHARMACEUTICAL INC.

Net worth: 968 158 $ as of 2026-05-30

66 year
Health Technology
Consumer Services
Commercial Services

Profile

Michael A. Narachi is an Independent Director at Ultragenyx Pharmaceutical, Inc. since 2015.
Formerly, Mr. Narachi was President, Chief Executive Officer & Director at CODA Biotherapeutics, Inc. from 2018 to 2022; President, Chief Executive Officer & Director at Orexigen Therapeutics, Inc. from 2016 to 2018; Chairman, President & Chief Executive Officer at Ren Pharmaceuticals, Inc. from 2006 to 2009; Chairman at Celladon Corp.
from 2013 to 2016; Executive Chairman at Naryx Pharma, Inc. from 2002 to 2008; Director at Pharmaceutical Research & Manufacturers of America from 2013 to 2017; Director at AMAG Pharmaceuticals, Inc. in 2014; Vice President at Amgen, Inc. from 1984 to 2003; and held director and vice president roles at Thousand Oaks Corp., Biotechnology Innovation Organization, and Amgen KK.
Education includes undergraduate and graduate degrees from the University of California, Davis, and an MBA from UCLA Anderson School of Management.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-05-13 40,441 ( 0.04% ) 968 158 $ 2026-05-30

Michael Narachi active positions

CompaniesPositionStart
ULTRAGENYX PHARMACEUTICAL INC. Director/Board Member 2015-02-19

Former positions of Michael Narachi

CompaniesPositionEnd
Chief Executive Officer 2022-09-30
OREXIGEN THERAPEUTICS, INC. Chief Executive Officer 2018-07-31
Director/Board Member 2017-03-31
Chairman 2016-02-29
AMAG PHARMACEUTICALS, INC. Chairman 2014-04-14
See the detail of Michael Narachi's experience

Training of Michael Narachi

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

74

1st degree connections

14

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies14

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Distribution Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Michael Narachi